Action - Reaction Desired - DON'T REACT Are conclusions being drawn too early?
Shall we let the chess game play out?
Bubbly's on ice..It's fun to be part of this rollarcoaster journey when the key to a doorway is simply a drug that will wipe out NSAIDS. Death of NSAIDS coming! Multiple doses. Multiple indications (prescription) and applications (non-prescription).
Make whatever decisions to get in or get out, but a line in the sand has been drawn, and the company says billions are ahead! Bottom line - it looks like it's only up from here (outside of massive criminal shorting that will expose an entire industry that needs media coverage). This is stealing. If you want a 10-bagger all you have to do is hold and let the drug speak for itself. It's very clear what the Phase 3 results will be from the medical perspective.
And yes, ATB-346 alone is worth over $1B. This is the hottest drug in the world (outside of COVID-19 therapeutics) for an acquisition. Do you want to buy now or wait for more wealth to come in?? Proof of the entire Hydrogen Sulfide Pipeline with different doses and different medical applications - financial people what's that worth? You need to know the individual medical markets right? % thereof based on some model like DCF? Do these non-medical people actually KNOW what they are doing? They need a young and brilliant doctor to be the CEO (Dan and Dr. Wallace are just too old). Long-term this is a series of transactions ahead for people that know how to use this key to open all kinds of doors to big money in medical markets.
GIDDY UP ECHELON - where's the money? Are you lying about the true value of ATE.V because you overvalue your own "Canadian" money? Fools. Let's change that - I'm waiting on Dan to make a call. But the people that are making money now aren't going to be happy because I can take that away from them. Echelon and co. seriously HARMED Antibe. Screw your sh*t money - lets get some real money in. The entire stampede below $0.89 on June 1st could have been avoided if Echelon and co. didn't get greedy and take advantage of the company. Pure vultures. Open at $1.40 at least (as THEY stated), rather than influencing the company to masquerade the Phase 2B results NR, to drop this. The gap in $0.89 - $1.40/2.00 needs to come back to shareholders.
I think it may be time for a new CEO. The new CEO should have a vested interest in the public markets and public opinion. This is about making everyone happy and Dan unfortunately failed.